LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

1.8 1.69

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.79

Max

1.8599999999999999

Pagrindiniai rodikliai
By Trading Economics
Pajamos	363K -7M
Pardavimai	634K 1.9M
Pelno marža	-369.064
Darbuotojai	74
EBITDA	420K -6.9M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+120.99% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-02

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	4.8M 161M
Ankstesnė atidarymo kaina	0.11
Ankstesnė uždarymo kaina	1.8

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

1.25 / 1.48 Palaikymas ir pasipriešinimas

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-01 23:35; UTC

Svarbiausios naujienos

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026-03-01 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026-03-01 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026-03-01 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026-03-01 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026-03-01 23:19; UTC

Svarbiausios naujienos

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026-03-01 23:17; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026-03-01 23:14; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026-03-01 22:55; UTC

Svarbiausios naujienos

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026-03-01 22:54; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026-03-01 22:53; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026-03-01 22:38; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026-03-01 22:21; UTC

Uždarbis

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026-03-01 22:17; UTC

Rinkos pokalbiai

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026-03-01 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026-03-01 22:00; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026-03-01 21:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026-03-01 21:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026-03-01 21:30; UTC

Rinkos pokalbiai

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026-03-01 21:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026-03-01 21:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026-03-01 20:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026-03-01 20:40; UTC

Rinkos pokalbiai

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026-03-01 20:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

120.99% į viršų

12 mėnesių prognozė

Vidutinis 4 USD 120.99%

Aukščiausias 4 USD

Žemiausias 4 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.